---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-288305"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T16:05:46.884338+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OmniAb expects $25M milestone payment from Janssen after first US commercial sale of TECVAYLI

## Summary
- Janssen notified OmniAb that first US commercial sale of TECVAYLI (teclistamab) occurred, triggering $25M milestone.
- OmniAb expects to receive the $25M payment and recognize $25M milestone revenue in Q4 2022.
- Milestone arises from licensing agreement between OmniAb and an affiliate of Janssen.

## SEC filing metadata
- accession: 0001193125-22-288305
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000119312522288305/0001193125-22-288305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000119312522288305/d390698d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-288305
- JSON: https://secwatch.observer/filing/0001193125-22-288305.json
- Plain text: https://secwatch.observer/filing/0001193125-22-288305.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.